Europe’s medicines regulator has approved a biosimilar of Rituxan/MabThera (rituximab), developed by Pfizer (NYSE: PFE).
Branded Ruxience, the monoclonal antibody is cleared for marketing in multiple indications including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA).
Approved in the USA in July 2019, Ruxience is part of a growing American market for biosimilars of the blockbuster biologic, with Celltrion (Kosdaq: 068270) and Teva Pharmaceutical (NYSE: TEVA) debuting their version, Truxima, in late 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze